MidEuropa Backs FAMAR’s Expansion of Sterile Manufacturing Footprint

MidEuropa, the leading European private equity investor with deep roots in Central Europe, announces today that its portfolio company FAMAR signed an agreement to acquire a production site dedicated to sterile manufacturing in Homburg (Saar), Germany, from MiP Pharma.

The addition of the Homburg site will strengthen FAMAR’s footprint in high-value dosage forms and expand its capabilities in aseptic and lyophilised fill & finish. With the addition of this state-of-the-art site, FAMAR will operate seven facilities across Europe, enhancing its ability to serve its customers with flexible, high-quality, and scalable production solutions across a variety of dosage forms.

“With support from MidEuropa, we are able to materially accelerate our value creation plan”, said Konstantinos Rengis, CEO of FAMAR. “The Homburg facility offers us the opportunity to expand our business with international clients. There is scarcity in high-quality sterile infrastructure in Europe and the investment will provide us immediate capacity for our growing business”, he added.

“We are delighted to support FAMAR on its mission to serve its global customer base in a flexible and comprehensive way. The acquisition of the Homburg site demonstrates MidEuropa’s strong commitment to support FAMAR as it accelerates its expansion into value-added formulations and service offerings”, said Matthew Strassberg, Partner and Head of Healthcare at MidEuropa.